PROTOCOL SEARCH

Brain

N0776 SUSPENDED

Protocol Document: N0776 SUSPENDED
Protocol Number: N0776 SUSPENDED
Phase II Trial of Avastin in Combination with Sorafenib in Recurrent Glioblastoma Multiforme
Trial Type: Clinical

N0877 Open to Phase 1 Only at this time

Protocol Document: N0877 Open to Phase 1 Only at this time
Protocol Number: N0877 Open to Phase 1 Only at this time
Phase I Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standar Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme
Trial Type: Clinical

R0825

Protocol Document: R0825
Protocol Number: R0825
Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab vs. Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma
Trial Type: Clinical

N0577

Protocol Document: N0577
Protocol Number: N0577
Phase III Intergroup Study of Radiotherapy vs. Temozolomide Alone vs. Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma
Trial Type: Clinical

Breast

S0221

Protocol Document: S0221
Protocol Number: S0221
Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer.
Trial Type: Clinical

893052

Protocol Document: 893052
Protocol Number: 893052
Phase III Trial of Adjuvant Therapy with Tamoxifen Alone or combined with Fluoxymesterone in Post-Menopausal Women with Resected Estrogen Receptor Positive Breast Cancer.
Trial Type: Clinical

E2197

Protocol Document: E2197
Protocol Number: E2197
Phase III Study of Adriamycin/Taxotere vs. Adriamycin/Cytoxan in Adjuvant Treatment of Node+ and High Rise Node- Breast Cancer
Trial Type: Clinical

E2Z04

Protocol Document: E2Z04
Protocol Number: E2Z04
Quality of Life in Younger Breast Cancer Survivors
Trial Type: Clinical

MA.17R

Protocol Document: MA.17R
Protocol Number: MA.17R
Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed iwth Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in MA.17 Study)
Trial Type: Clinical

N0336

Protocol Document: N0336
Protocol Number: N0336
Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Oral Agent in Patients with Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane
Trial Type: Clinical

N063I

Protocol Document: N063I
Protocol Number: N063I
Charnges in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy
Trial Type: Clinical

S0012

Protocol Document: S0012
Protocol Number: S0012
A COMPARATIVE RANDOMIZED STUDY OF STANDARD DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY WEEKLY PACLITAXEL VS. WEEKLY DOXORUBICIN AND DAILY ORAL CYCLOPHOSPHAMIDE PLUS G-CSF FOLLOWED BY WEEKLY PACLITAXEL AS NEOADJUVANT THERAPY FOR INFLAMMATORY AND LOCALLY ADVANCED BREAST CANCER
Trial Type: Clinical

S0226 - Pharmacokinetic component closed

Protocol Document: S0226 - Pharmacokinetic component closed
Protocol Number: S0226 - pharmacokinetic component closed
PHASE III RANDOMIZED TRIAL OF ANASTROZOLE VERSUS ANASTROZOLE AND FULVESTRANT AS FIRST LINE THERAPY FOR POST MENOPAUSAL WOMAN WITH METASTATIC BREAST CANCER
Trial Type: Clinical

Z1031 TCOP Closure

Protocol Document: Z1031 TCOP Closure
Protocol Number: Z1031
Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane, Letrozole or Anastrozole in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Trial Type: Clinical

B-39 BAHO Sub-Study Closed

Protocol Document: B-39 BAHO Sub-Study Closed
Protocol Number: B-39 BAHO Sub-Study Closed
A RANDOMIZED PHASE III STUDY OF CONVENTIONAL WHOLE BREAST IRRADIATION (WBI) VERSUS PARTIAL BREAST IRRADIATION (PBI) FOR WOMEN WITH STAGE 0, I, OR II BREAST CANCER.
Trial Type: Clinical

CALGB 40603

Protocol Document: CALGB 40603
Protocol Number: CALGB 40603
Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor Poor/HER 2 Negative Resectable Breast Cancer
Trial Type: Clinical

B 43

Protocol Document: B 43
Protocol Number: B 43
Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2 Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Trial Type: Clinical

B 44I - call for consent

Protocol Document: B 44I - call for consent
Protocol Number: B 44I - call for consent
Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2 Positive Node-Positive or High Risk Node Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
Trial Type: Clinical

N063D Design 2B

Protocol Document: N063D Design 2B
Protocol Number: N063D
ALTTO Study. Ajuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study. A Randomized, Multi-Center, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Trial Type: Clinical

N0733

Protocol Document: N0733
Protocol Number: N0733
Randomized Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients with HER2+ Breast Cancer Previously Treated with Trastuzumab and an Anthracycline and/or a Taxane
Trial Type: Clinical

CALGB 40502

Protocol Document: CALGB 40502
Protocol Number: CALGB 40502
Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound NAB-Paclitaxel or Ixabepilone Combined with Bevacizumab as First-Line therapy for Locally Recurrent or Metastatic Breast Cancer
Trial Type: Clinical

S0500

Protocol Document: S0500
Protocol Number: S0500
Randomized Phase III Trial to Test the Strategy of Changing Therapy vs. Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment.
Trial Type: Clinical

C70301 (substudy to C40101)

Protocol Document: C70301 (substudy to C40101)
Protocol Number: C70301 (substudy to C40101)
Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer
Trial Type: Clinical

Z1071

Protocol Document: Z1071
Protocol Number: Z1071
Phase II Study Evaluating the Role of Sentinel Lymph Node Surgery and Axillary Lymph Node Dissection Following Preoperative Chemotherapy in Women with Node Positive Breast Cancer (T1-4, N1-2, M0) at Initial Diagnosis
Trial Type: Clinical

Cancer Control

CALGB 170601

Protocol Document: CALGB 170601
Protocol Number: CALGB 170601
Phase III Double-Blind Trial of Oral Duloxetine for Treatment of Pain Associated with Chemotherapy-Induced Peripheral Neuropathy
Trial Type: Clinical

CALGB 70604

Protocol Document: CALGB 70604
Protocol Number: CALGB 70604
Randomized Phase III Study of Standard Dosing vs. Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
Trial Type: Clinical

N07C2

Protocol Document: N07C2
Protocol Number: N07C2
The Use of Wisconsin Ginseng (panax quinquefoliuis) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Trial Type: Clinical

N08C1 B closed; C minority only - A/D general

Protocol Document: N08C1 B closed; C minority only - A/D general
Protocol Number: N08C1 B Closed; C minority only - A/D general
Paclitaxel-Associated Acute Pain Syndrome Natural History Study
Trial Type: Clinical

N08C3

Protocol Document: N08C3
Protocol Number: N08C3
Phase III Double-Blind, Placebo-Controlled Study of Gabapentin for the Preventino of Delayed CINV (Chemotherapy Induced Nausea and Vomiting) in Patients Receiving Highly Emetogenic Chemotherapy
Trial Type: Clinical

N08C7 Closed to general - open minority only

Protocol Document: N08C7 Closed to general - open minority only
Protocol Number: N08C7 closed to general - open minority only
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Flaxseed for Treatment of Hot Flashes
Trial Type: Clinical

RC08C6

Protocol Document: RC08C6
Protocol Number: RC08C6
White Wine for Appetite Loss: A Randomized, Controlled Trial
Trial Type: Clinical

RC08CC

Protocol Document: RC08CC
Protocol Number: RC08CC
The Use of Calcium and Magnesium for Prevention of Ixabepilone Induced Peripheral Neuropathy: A Phase III Double-Blind, Placebo-Controlled Study
Trial Type: Clinical

S0702

Protocol Document: S0702
Protocol Number: S0702
A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment
Trial Type: Clinical

WFU 97405 Suspended

Protocol Document: WFU 97405 Suspended
Protocol Number: WFU 97405
Randomized Study of Soy Protein and Effexor on Vasomotor Symptoms of Men with Prostate Cancer
Trial Type: Clinical

N04C2

Protocol Document: N04C2
Protocol Number: N04C2
An Exploratory, Randomzied, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR Depot) for Symptomatic Ascites in Cancer Patients
Trial Type: Clinical

Gastrointestinal

E5202

Protocol Document: E5202
Protocol Number: E5202
Randomized Phase III Study Comparing 5FU, Leucovorin and Oxaliplatin vs. 5FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Marks
Trial Type: Clinical

S0809

Protocol Document: S0809
Protocol Number: S0809
Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC)
Trial Type: Clinical

N0346

Protocol Document: N0346
Protocol Number: N0346
Phase II Trial of Celecoxib and Capecitabine Combined with Pelvic Irradiation as Neoadjuvant Treatment of Stage II or III Adenocarcinoma of the Rectum
Trial Type: Clinical

RC0948

Protocol Document: RC0948
Protocol Number: RC0948
The Oncotype DX Colon Cancer Assay for Stage II Colon Carcinoma: Does it Impact Physician Adjuvant Treatment Decision Making and Patient Satisfaction.
Trial Type: Clinical

N0747

Protocol Document: N0747
Protocol Number: N0747
Randomzied Phase II Trial of Sunitinib Plus Capecitabine vs. Capecitabine Alone (With the Potential for Cross Over) for Elderly and/or Poor Performance Status Patients with Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
Trial Type: Clinical

N0849 SUSPENDED

Protocol Document: N0849 SUSPENDED
Protocol Number: N0849
Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Gastric Cardia
Trial Type: Clinical

CALGB 80802

Protocol Document: CALGB 80802
Protocol Number: CALGB 80802
Phase III Randomized Study of Sorafenib (IND 69896, NSC 724772) Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)
Trial Type: Clinical

CALGB 80405

Protocol Document: CALGB 80405
Protocol Number: CALGB 80405
Phase III Trial of Irinotecan/5FU/Leucovorin or Oxaliplatin/5FU/Leucovorin with Bevacizumab, or Cetuximab (C225) or With The Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Trial Type: Clinical

S0600

Protocol Document: S0600
Protocol Number: S0600
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab With or Without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who Have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX
Trial Type: Clinical

E3205

Protocol Document: E3205
Protocol Number: E3205
Phase II Trial of Cetuximab Plus Cisplatin, 5 FU and Radiation in Immunocompetent Patients with Anal Carcinoma
Trial Type: Clinical

N0543

Protocol Document: N0543
Protocol Number: N0543
Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin and Capecitabine as First-Line Therapy for Advanced Small Bowel Adenocarcinoma
Trial Type: Clinical

Genitourinary

CALGB 90401

Protocol Document: CALGB 90401
Protocol Number: CALGB 90401
Randomized Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab in Men with Hormone Refractory Prostate Cancer
Trial Type: Clinical

R0232

Protocol Document: R0232
Protocol Number: R0232
Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma
Trial Type: Clinical

R0526

Protocol Document: R0526
Protocol Number: R0526
A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam Radiotherapy.
Trial Type: Clinical

R0534

Protocol Document: R0534
Protocol Number: R0534
Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (Sport) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
Trial Type: Clinical

R0815

Protocol Document: R0815
Protocol Number: R0815
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer
Trial Type: Clinical

R0831 SUSPENDED

Protocol Document: R0831 SUSPENDED
Protocol Number: R0831 SUSPENDED
Randomized, Double-Blind, Placebo-Controlled Phase III Trial To Evaluate the Effectiveness of a Phosphodiesterate 5 Inhibitor, Tadalafil, in Prevention of Erectile Dysfunction in Patients Treated with Radiotherapy for Prostate Cancer
Trial Type: Clinical

E2804 Adv. MRI Image - closed

Protocol Document: E2804 Adv. MRI Image - closed
Protocol Number: E2804 Adv. MRI Image - closed
A Randomized Phase II Study of VEGF, RAF Kinase, and MTOR Combination GTargeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
Trial Type: Clinical

E2805 Study to close 9/1/10

Protocol Document: E2805 Study to close 9/1/10
Protocol Number: E2805
Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs. Sorafenib vs. Placebo in Patients with Resected Renal Cell Carcinoma
Trial Type: Clinical

CALGB 90601

Protocol Document: CALGB 90601
Protocol Number: CALGB 90601
Randomized, Double-Blind, Phase III Study Comparing Gemcitabine, Cisplatin and Bevacizumab to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma
Trial Type: Clinical

Head and Neck

E1308

Protocol Document: E1308
Protocol Number: E1308
Phase II Trial of Inductino Chemotherapy Followed by Cetuximab with Low Dose vs. Standard Dose IMRT in Patients with HPV-Associated Resectable Squamous Cell Carcinoma for the Oropharynx
Trial Type: Clinical

R0537 Phase II Closed

Protocol Document: R0537 Phase II Closed
Protocol Number: R0537 Phase II Closed
Phase II/III Study Comparing Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) vs. Pilocarpine in Treating Early Radiation-Induced Xerostomia
Trial Type: Clinical

R0920

Protocol Document: R0920
Protocol Number: R0920
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Trial Type: Clinical

Hematology

E2905

Protocol Document: E2905
Protocol Number: E2905
Randomized Phase III Trial Comparing the Frequency of MajorErythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low or Intermediate - 1 Risk MDS and Symptomatic Anemia
Trial Type: Clinical

RC0783

Protocol Document: RC0783
Protocol Number: RC0783
Randomzied Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab With or Without Current Avastin for Previouly Untreated B-Chronic Lymphocytic Leukemia (CLL)
Trial Type: Clinical

S0816 - Special Regulatory with AG Mednet System

Protocol Document: S0816 - Special Regulatory with AG Mednet System
Protocol Number: S0816 - Special Regulatory with AG Mednet System
Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
Trial Type: Clinical

S0777

Protocol Document: S0777
Protocol Number: S0777
Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) and Low Dose Dexamethasone (LLD) vs. Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD), for Induction in Patients with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant
Trial Type: Clinical

Lung

S0220

Protocol Document: S0220
Protocol Number: S0220
A PHASE II TRIAL OF INDUCTION CHEMORADIOTHERAPY WITH CISPLATIN/ETOPOSIDE FOLLOWED BY SURGICAL RESECTION, FOLLOWED BY DOCETAXEL, FOR NON-SMALL CELL LUNG CANCER INVOLVING THE SUPERIOR SULCUS (PANCOAST TUMORS)
Trial Type: Clinical

CALGB 30607

Protocol Document: CALGB 30607
Protocol Number: CALGB 30607
Randomized Phase III, Placebo-Controlled Trial of Sunitinib as Maintenance therapy in Non-Progressing Patients Following an Initial Foru Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer
Trial Type: Clinical

E1505

Protocol Document: E1505
Protocol Number: E1505
Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients with Completely Resected Stage IB - IIIA Non-Small Cell Lung Cancer
Trial Type: Clinical

E4508

Protocol Document: E4508
Protocol Number: E4508
Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both for Advanced Non-Small Cell Lung Cancer Patients Who Will Not Receive Bevacizumab-Based Therapy
Trial Type: Clinical

N0821

Protocol Document: N0821
Protocol Number: N0821
A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Non-Squamous, Non-Small Cell Lung Cancer Evaluating Efficacy and Tolerability in Elderly Patients (age greater than 70 years) with Good Performance Status (PS less than 2)
Trial Type: Clinical

R0617

Protocol Document: R0617
Protocol Number: R0617
A Rnaodmized Phase III Comparison of Standard Dose (60 Gy) vs. High Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer
Trial Type: Clinical

R0813

Protocol Document: R0813
Protocol Number: R0813
Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer in Medically Inoperable Patients
Trial Type: Clinical

R0915

Protocol Document: R0915
Protocol Number: R0915
Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage 1 Peripheral Non-Small Cell Lung Cancer
Trial Type: Clinical

S0424

Protocol Document: S0424
Protocol Number: S0424
Molecular Epidemiology Case-Series Study of Non-Small CellLung Cancer in Smoking and Non-Smoking Women and Men
Trial Type: Clinical

S0819

Protocol Document: S0819
Protocol Number: S0819
Randomized Phase III Study Comapring Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer
Trial Type: Clinical

E1508

Protocol Document: E1508
Protocol Number: E1508
Randomized Phase II Study of Cisplatin and Etoposide in Combination with Either Hedgehog Inhibitor GDC-0449 or IG-1R Monoclonal Antibody IMC-A12 for Patients with Extensive Stage Small Cell Lung Cancer
Trial Type: Clinical

N0923

Protocol Document: N0923
Protocol Number: N0923
A Randomized Double-Blinded Phase II Study of NTX-010, a Replication-Competent Picornavirus, After Standard Platinum-Containing Induction Regimens of Cytoreductive Chemotherapy for Patients with Extensive Stage Small Cell Lung Carcinoma
Trial Type: Clinical

R0937

Protocol Document: R0937
Protocol Number: R0937
Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer
Trial Type: Clinical

Melanoma

E1697

Protocol Document: E1697
Protocol Number: E1697
Randomized Study of Four Weeks High Dose IFN-12B In Stage IIA Melanoma
Trial Type: Clinical

N0879 SUSPENDED

Protocol Document: N0879 SUSPENDED
Protocol Number: N0879
Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or Without Everolimus for Therapy of Metastatic Malignant Melanoma
Trial Type: Clinical

Patient Satisfaction Survey

N0392 - NCCTG Companion Study

Protocol Document: N0392 - NCCTG Companion Study
Protocol Number: N0392 - NCCTG Companion Study
Assessment of Patient Satisfaction with Participation in Phase II/III NCCTG Clinical trials
Trial Type: Clinical

Pharmaceutical

20062080

Protocol Document: 20062080
Protocol Number: 20062080
Phase 2, Randomized Trial of Chemoradiation with or without Panitumumab in Subjects with Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Trial Type: Clinical

AVF3991 - NSCL only

Protocol Document: AVF3991 - NSCL only
Protocol Number: AVF3991 - NSCL only
An Observational Study of Avastin in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology, or Locally Recurrent of Metastatic Breast Cancer)
Trial Type: Clinical

H8K-MC-JZAO Call TCOP

Protocol Document: H8K-MC-JZAO Call TCOP
Protocol Number: H8K-MC-JZAO
Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma
Trial Type: Clinical

20060392 Call TCOP

Protocol Document: 20060392 Call TCOP
Protocol Number: 20060392
Prospective Multi-National Observational Study to Assess Health Resource Utilization Associated with Skeletal Related Events in Patients with Bone Metastases Secondary to Breast, Prostate, or Lung Cancer, or Multiple Myeloma.
Trial Type: Clinical

Unknown Primary

N0871

Protocol Document: N0871
Protocol Number: N0871
Phase II Study of Carboplatin, Paclitaxel and Everolimus in Previously Untreated Patients with Measurable Disease with Cancer of Unknown Primary
Trial Type: Clinical